Neurocrine Biosciences, Inc. (NBIX) CEO Sells $8,505,135.75 in Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kevin Charles Gorman sold 105,983 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $80.25, for a total value of $8,505,135.75. Following the completion of the sale, the chief executive officer now directly owns 339,482 shares of the company’s stock, valued at $27,243,430.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Kevin Charles Gorman also recently made the following trade(s):
- On Tuesday, January 16th, Kevin Charles Gorman sold 3,750 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $78.89, for a total value of $295,837.50.
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at $79.28 on Friday. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $7,020.00, a P/E ratio of -35.71, a P/E/G ratio of 13.72 and a beta of 0.26. Neurocrine Biosciences, Inc. has a 52-week low of $39.21 and a 52-week high of $91.82.
Several institutional investors and hedge funds have recently modified their holdings of NBIX. The Manufacturers Life Insurance Company increased its position in shares of Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after acquiring an additional 193 shares during the last quarter. Crow Point Partners LLC purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $145,000. American International Group Inc. purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $161,000. M&T Bank Corp purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $202,000. Finally, Mission Wealth Management LP purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $204,000.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.